Interestingly, we found that PGRN as a key regulator of inflammation was associated with recurrence in HR-positive breast cancer in which endocrine therapy is effective, while adiponectin as a key regulator of insulin resistance was associated with recurrence in HR-negative breast cancer in which endocrine therapy is not effective. This evidence concerns the gene GRN and Insulin resistance.